
ANL Stock Forecast & Price Target
ANL Analyst Ratings
Bulls say
Adlai Nortye Ltd demonstrates a positive outlook due to its diverse and promising pipeline, particularly with candidate AN8025, which has shown preclinical data indicating enhanced T cell responses and effective modulation of antigen presenting cells, surpassing existing treatments. Furthermore, the company is well-positioned with AN9025, a pan-KRAS inhibitor, targeting a critical unmet need in addressing various KRAS mutations beyond the KRAS-G12C variant, thereby expanding its therapeutic potential in oncology. These innovative developments in cancer therapy, coupled with strong scientific backing, highlight the company's capability to advance its clinical programs and meet significant market demands.
Bears say
Adlai Nortye Ltd has faced significant setbacks with the disappointing results from its buparlisib program, leading to its discontinuation. This failure highlights broader concerns regarding the company's ability to navigate clinical trials successfully, as well as its capacity to secure necessary funding for the progression of its drug development initiatives. Additionally, the risk of dilutive capital raises poses a further challenge to the company's financial stability and overall outlook.
This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.
ANL Analyst Forecast & Price Prediction
Start investing in ANL
Order type
Buy in
Order amount
Est. shares
0 shares